The emerging roles of YAP and TAZ in cancer (original) (raw)

• Pan, D. The Hippo signaling pathway in development and cancer. Dev. Cell 19, 491–505 (2010).
  Article CAS Google Scholar
• Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nature Rev. Cancer 13, 246–257 (2013).
  Article CAS Google Scholar
• Mo, J. S., Park, H. W. & Guan, K. L. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 15, 642–656 (2014).
  Article CAS Google Scholar
• Johnson, R. & Halder, G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nature Rev. Drug Discov. 13, 63–79 (2014).
  Article CAS Google Scholar
• Nishioka, N. et al. The Hippo signaling pathway components LATS and YAP pattern TEAD4 activity to distinguish mouse trophectoderm from inner cell mass. Dev. Cell 16, 398–410 (2009).
  Article CAS Google Scholar
• Xin, M. et al. Hippo pathway effector YAP promotes cardiac regeneration. Proc. Natl Acad. Sci. USA 110, 13839–13844 (2013).
  Article CAS Google Scholar
• Varelas, X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141, 1614–1626 (2014).
  Article CAS Google Scholar
• Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nature Cell Biol. 15, 637–646 (2013).
  Article CAS Google Scholar
• Zhang, J. et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biol. 11, 1444–1450 (2009).
  Article CAS Google Scholar
• Fujii, M. et al. TGFβ synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J. Exp. Med. 209, 479–494 (2012).
  Article CAS Google Scholar
• Aragona, M. et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154, 1047–1059 (2013).
  Article CAS Google Scholar
• Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179–183 (2011).
  Article CAS Google Scholar
• Friedl, P. & Alexander, S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992–1009 (2011).
  Article CAS Google Scholar
• Tang, Y. et al. MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev. Cell 25, 402–416 (2013).
  Article CAS Google Scholar
• Zhao, B. et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26, 54–68 (2012).
  Article Google Scholar
• Codelia, V. A., Sun, G. & Irvine, K. D. Regulation of YAP by mechanical strain through JNK and Hippo signaling. Curr. Biol. 24, 2012–2017 (2014).
  Article CAS Google Scholar
• Yu, F. X. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780–791 (2012).
  Article CAS Google Scholar
• Zhao, B. et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25, 51–63 (2011).
  Article Google Scholar
• Adler, J. J. et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc. Natl Acad. Sci. USA 110, 17368–17373 (2013).
  Article CAS Google Scholar
• O'Hayre, M. et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nature Rev. Cancer 13, 412–424 (2013).
  Article CAS Google Scholar
• Chen, D. et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo–YAP pathway and a prognostic marker. Nature Med. 18, 1511–1517 (2012).
  Article CAS Google Scholar
• Fan, R., Kim, N. G. & Gumbiner, B. M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl Acad. Sci. USA 110, 2569–2574 (2013).
  Article CAS Google Scholar
• Azzolin, L. et al. YAP/TAZ incorporation in the β-Catenin destruction complex orchestrates the WNT response. Cell 158, 157–170 (2014).
  Article CAS Google Scholar
• Barry, E. R. et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106–110 (2013).
  Article Google Scholar
• Heallen, T. et al. Hippo pathway inhibits WNT signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458–461 (2011).
  Article CAS Google Scholar
• Rosenbluh, J. et al. β-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457–1473 (2012).
  Article CAS Google Scholar
• Varelas, X. et al. The Hippo pathway regulates WNT/β-catenin signaling. Dev. Cell 18, 579–591 (2010).
  Article CAS Google Scholar
• Varelas, X. et al. TAZ controls SMAD nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nature Cell Biol. 10, 837–848 (2008).
  Article CAS Google Scholar
• Alarcon, C. et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGFβ pathways. Cell 139, 757–769 (2009).
  Article CAS Google Scholar
• Attisano, L. & Wrana, J. L. Signal integration in TGFβ, WNT, and Hippo pathways. F1000Prime Rep. 5, 17 (2013).
  Article Google Scholar
• Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R. & Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genet. 39, 673–677 (2007).
  Article CAS Google Scholar
• Mori, M. et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 156, 893–906 (2014).
  Article CAS Google Scholar
• Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747–2761 (2007).
  Article CAS Google Scholar
• Chaulk, S. G., Lattanzi, V. J., Hiemer, S. E., Fahlman, R. P. & Varelas, X. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7. J. Biol. Chem. 289, 1886–1891 (2014).
  Article CAS Google Scholar
• Hong, J. H. et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309, 1074–1078 (2005).
  Article CAS Google Scholar
• Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759–772 (2011).
  Article CAS Google Scholar
• Skibinski, A. et al. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep. 6, 1059–1072 (2014).
  Article CAS Google Scholar
• Yimlamai, D. et al. Hippo pathway activity influences liver cell fate. Cell 157, 1324–1338 (2014).
  Article CAS Google Scholar
• Chan, S. W. et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68, 2592–2598 (2008).
  Article CAS Google Scholar
• Reginensi, A. et al. YAP- and CDC42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet. 9, e1003380 (2013).
  Article CAS Google Scholar
• Zhang, N. et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27–38 (2010).
  Article CAS Google Scholar
• Liu-Chittenden, Y. et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300–1305 (2012).
  Article CAS Google Scholar
• Zhang, W. et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 7, ra42 (2014).
  Article Google Scholar
• Kapoor, A. et al. YAP1 activation enables bypass of oncogenic kras addiction in pancreatic cancer. Cell 158, 185–197 (2014).
  Article CAS Google Scholar
• Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171–184 (2014).
  Article CAS Google Scholar
• Shackelford, D. B. & Shaw, R. J. The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nature Rev. Cancer 9, 563–575 (2009).
  Article CAS Google Scholar
• Mohseni, M. et al. A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway. Nature Cell Biol. 16, 108–117 (2014).
  Article CAS Google Scholar
• Tumaneng, K. et al. YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29. Nature Cell Biol. 14, 1322–1329 (2012).
  Article CAS Google Scholar
• Feng, X. et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25, 831–845 (2014).
  Article CAS Google Scholar
• Yu, F. X. et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25, 822–830 (2014).
  Article CAS Google Scholar
• Wang, L. et al. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS ONE 8, e65539 (2013).
  Article CAS Google Scholar
• Liu, G. et al. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene http://dx.doi.org/10.1038/onc.2014.281 (2014).
• Nguyen, H. T. et al. Viral small T oncoproteins transform cells by alleviating Hippo-pathway-mediated inhibition of the YAP proto-oncogene. Cell Rep. 8, 707–713 (2014).
  Article CAS Google Scholar
• Imajo, M., Miyatake, K., Iimura, A., Miyamoto, A. & Nishida, E. A molecular mechanism that links Hippo signalling to the inhibition of WNT/β-catenin signalling. EMBO J. 31, 1109–1122 (2012).
  Article CAS Google Scholar
• Levy, D., Adamovich, Y., Reuven, N. & Shaul, Y. YAP1 phosphorylation by c-ABL is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol. Cell 29, 350–361 (2008).
  Article CAS Google Scholar
• Cottini, F. et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nature Med. 20, 599–606 (2014).
  Article CAS Google Scholar
• Yoo, H. Y. et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nature Genet. 46, 371–375 (2014).
  Article CAS Google Scholar
• Koontz, L. M. et al. The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev. Cell 25, 388–401 (2013).
  Article CAS Google Scholar
• Jiao, S. et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25, 166–180 (2014).
  Article CAS Google Scholar
• Sorrentino, G. et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nature Cell Biol. 16, 357–366 (2014).
  Article CAS Google Scholar
• Wang, Z. et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl Acad. Sci. USA 111, E89–E98 (2014).
  Article CAS Google Scholar
• Gronich, N. & Rennert, G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nature Rev. Clin. Oncol. 10, 625–642 (2013).
  Article CAS Google Scholar
• Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
  Article CAS Google Scholar
• Nguyen, H. B., Babcock, J. T., Wells, C. D. & Quilliam, L. A. LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of YAP. Oncogene 32, 4100–4109 (2013).
  Article CAS Google Scholar
• Moya, I. M. & Halder, G. Discovering the Hippo pathway protein–protein interactome. Cell Res. 24, 137–138 (2014).
  Article CAS Google Scholar